Clinical Trials
15 trialsNCT07216703 2026-05-22
TroFuse-036
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06023862 2026-05-06
DOVE
Yonsei University
Phase 2 Recruiting
NCT07146919 2026-04-23
ANGELICA
Centre Leon Berard
Phase 1/2 Withdrawn
NCT03556839 2026-04-21
BEATcc
Grupo Español de Investigación en Cáncer de Ovario
Phase 3 Completed
NCT03786081 2026-04-14
Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer
Seagen Inc.
Phase 1/2 Terminated
NCT07497074 2026-03-27
JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 2 Not yet recruiting
NCT07472153 2026-03-16
PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer
N.N. Alexandrov National Cancer Centre
Phase 2/3 Recruiting
NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT03635567 2026-02-04
KEYNOTE-826
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT07054567 2026-01-21
A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT06400472 2026-01-14
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Recruiting
NCT07080216 2026-01-05
Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Recruiting
NCT04982237 2025-11-19
A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
Akeso
Phase 3 Active not recruiting
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT06859775 2025-06-06
SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2 Recruiting